All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
New York Vol.37 (corporations: Regeneron)
上記リンク内に無い本日までのツイート
We’ve been named one of #AmericasMostJUST companies by @Forbes and @justcapital_ for our commitment to using our resources and expertise to make the world a better place. More on the #JUST100: https://t.co/7uCfrMZ9QD #ResponsibleRegeneron pic.twitter.com/4k7j6Dckzi
— Regeneron (@Regeneron) October 14, 2020
Today, the @EMA_News Committee for Medicinal Products for Human Use (CHMP) recommended the approval of our medicine for children aged 6-11 years with uncontrolled severe #AtopicDermatitis. Learn more: https://t.co/scFqqXQkxS Cc: @sanofi pic.twitter.com/Je5lWmqhZu
— Regeneron (@Regeneron) October 16, 2020
Entered into an agreement with the @Regeneron Genetics Center to advance the goal of the university, along with our partner hospitals @LeBonheurChild, to provide precision medicine tailored to the individual genomic characteristics of patients. https://t.co/NCcDXvzLSn pic.twitter.com/CFLhhDjJjc
— UTHSC (@uthsc) October 19, 2020
Kara and her family are at a standstill with eosinophilic esophagitis management. We’re working with @Regeneron to understand the causes of the disease for families around the world. pic.twitter.com/txk55TyB8i
— Sanofi Genzyme (@SanofiGenzyme) October 14, 2020
Eosinophilic esophagitis (#EoE) is an often misunderstood disease. With @Regeneron, we’re presenting late-breaking pivotal trial data on its management during #UEGWeek. pic.twitter.com/RJkiGhR8z3
— Sanofi (@sanofi) October 13, 2020
Today, our medicine was recommended for approval in children aged 6-11 years in Europe with severe #AtopicDermatitis by the @EMA_News Committee for Medicinal Products for Human Use (CHMP). Cc: @Regeneron Read the news: https://t.co/udUMDRgIws pic.twitter.com/N7eA8DyhE9
— Sanofi (@sanofi) October 16, 2020
Dr David Tucker and the team at @RCHTWeCare worked with @Regeneron to restart a trial of an investigational bio-engineered fully human monoclonal antibody which is being tested in patients with relapsed lymphoma.
Read about the steps they took: https://t.co/jWbzqmawHv@NIHRSW pic.twitter.com/jmkGeXgjTM
— NIHR for Industry (@NIHR_Industry) October 15, 2020
With @Sanofi and @Regeneron, we're seeking ideas to support people living with #AtopicDermatitis (AD). Join the ‘Agents of Change’ Challenge: Navigating Uncertainty to help people with AD feel more in control: https://t.co/FPTNYSphLX pic.twitter.com/3K8CxS5yEZ
— OpenIDEO (@OpenIDEO) October 19, 2020
From academics to CEO: Stephen Russell, the founder of Imanis Life Sciences, chats to us about Vyriad and partnership with @Regeneron https://t.co/vexbqZGWA1 pic.twitter.com/x8w8eGWGNx
— Decision Resources Group (@DRGinsights) October 16, 2020
https://twitter.com/NewomicsInc/status/1318634515590483971
Thank you to everyone who joined us for the 2020 #GeneExpression and Signaling in the #ImmuneSystem; including co-orgs Diane Mathis, Stephen Nutt, Alexander Rudensky, and Arthur Weiss; and sponsors @NIAIDNews and @Regeneron. #cshlimmune https://t.co/CBlzfEJwkg
— CSHL Meetings (@cshlmeetings) October 19, 2020
Sajith Wickramasekara was an MIT undergrad when he came up with a cloud-based Crispr design tool to help scientists. Eight years later, Regeneron, Gilead and hundreds of other companies use its collaborative software: https://t.co/brNNEmeURD
— Forbes (@Forbes) October 20, 2020
While @Regeneron is pushing its high-dose IV anti-SARS2 mAb cocktail (8g !!), researchers are developing inhaled low-dose anti-SARS2 mAbs (2mg-6mg !!). Potentially much cheaper and more user-friendly! https://t.co/xKzMDOmNar
— Julien Potet (@julienpotet) October 21, 2020
“…REGN-COV2 based therapy may offer clinical benefit in both prevention and treatment settings of #COVID19 disease, where it is currently being evaluated.”
Learn more about the recent findings of .@Regeneron’s antibody cocktail: https://t.co/xblmBjHGQX #SARSCoV2 #coronavirus pic.twitter.com/lRresg4e2S
— Genetic Engineering & Biotechnology News (@GENbio) October 17, 2020
The race we mentioned above got really interesting when we reported that Regeneron’s antibody treatment was tested using cells originally derived from an abortion. https://t.co/lNwUJwbf0R
— MIT Technology Review (@techreview) October 20, 2020
https://twitter.com/chngin_the_wrld/status/1318563734424449024
Today on @TheScienceShed with @SteveTheChemist we delve into the therapeutic that cured Trump, and discuss the insane mouse genetics technology from @Regeneron that allowed it to be made…. https://t.co/O30rIjn5Me
— Nick Evans (@theevanslab) October 19, 2020
.@Regeneron is conducting clinical trials on its monoclonal antibody #COVID19 therapy. If the trials are successful & the therapy receives Emergency Use Authorization from the FDA, Regeneron will provide it for free to Americans suffering from COVID-19: https://t.co/ufzHYm2pMP
— Alliance to Protect Medical Innovation (@ProtectMedicine) October 16, 2020
.@Regeneron asks @US_FDA for emergency clearance for #COVID19 therapy https://t.co/yM0KN6X4Pt pic.twitter.com/Cioxh2lF8X
— The Cancer Letter (@TheCancerLetter) October 13, 2020
A study of the REGN-COV2 #antibody cocktail in rhesus macaques and golden hamsters provides evidence it may offer clinical benefit in both prevention and treatment settings of #COVID19 disease. @Regeneron https://t.co/6E8jJFUTC3 pic.twitter.com/7HAQL4izfm
— Science Magazine (@ScienceMagazine) October 13, 2020
The #SARSCoV2 monoclonal antibody (mAb) rollout is going to be very complicated.https://t.co/0Vm6uvG8Yl@katie_thomas covers many issues here, including potential need for rapid antibody testing. Add this one:
These are outpatient infusions. Where is the mAb infusion clinic?— Eric Topol (@EricTopol) October 20, 2020
https://twitter.com/DelthiaRicks/status/1317565058998816776
President @realDonaldTrump is working with @US_FDA and @HHSGov to make the antibody treatment Regeneron available to everyone who needs it. pic.twitter.com/YSeT7deNMG
— The White House (@WhiteHouse) October 16, 2020
On the latest #TWiV Ari and Kishana founders of @BlackInMicro join TWiV to discuss goals of organization, then pauses of J&J and Lilly #COVID19 vaccine trials, preclin of Regeneron #SARSCoV2 mAb cocktail, reinfection of a patient in Nevada https://t.co/vIFfxIzZ57 pic.twitter.com/6Xj9jDzWH2
— Vincent Racaniello (@profvrr) October 15, 2020
Took a stab at explaining roughly how the @Regeneron antibody treatment is made. Strange its being dragged into US partisan politics, including controversies over the use of a 50 year old embryonic stem cell line. It represents a massive shift in the way we fix this pandemic: pic.twitter.com/Ycl9MZV9FG
— Kashif Pirzada, MD (@KashPrime) October 13, 2020
Did you know Regeneron's antibody cocktail for #COVID19 is being tested in RI? Here's my Q&A with the principal investigator where we discuss who's getting it and how it's going: https://t.co/dnxFhPA9up
— Kim Kalunian (@KimKalunian) October 20, 2020
.@SavannahGuthrie: "How severe were your symptoms, and in particular did you have pneumonia?"
President Trump: "I didn't feel good, I didn't feel strong … They gave me Regeneron and Remdesivir both and all I know is I felt good the following day."#TrumpTownHall pic.twitter.com/LLLZO5Rwu3
— NBC News (@NBCNews) October 16, 2020
Trump says he feels like 'Superman' after Regeneron COVID-19 treatment https://t.co/PLX4xTkOoS pic.twitter.com/6r0Becmpmn
— New York Post (@nypost) October 14, 2020
Donald Trump told the rally he "felt like Superman" after doctors gave him a COVID-19 antibody cocktail called Regeneron. #9News
https://t.co/SQ1H0jI6pm— 9News Australia (@9NewsAUS) October 19, 2020
https://twitter.com/stridermemes/status/1316766718207897601
Regeneron CEO says Trump's experience with the company's COVID-19 drug is the 'weakest evidence you can get' of whether it works https://t.co/DP3HMCz52i via @Yahoo
So much for @realDonaldTrump's infomercial hype.
— The Ghost of Lindsey Graham's Past (@PogoChrestman) October 13, 2020
Local biopharmo co. @Regeneron has been getting a lot of attention this month, though not all of it good. https://t.co/qSf31nsdlE
— Westchester Magazine (@WestchesterMag) October 18, 2020
The Regeneron therapy Trump took is a real menace. It's part of the Operation Warp Speed plan. Trump has promised his miracle cure will be delivered to seniors in nursing homes free of charge. https://t.co/geGZNcWhSq
— Julianne ✝️ (@KindeandTrue) October 20, 2020
No, Regeneron Did Not Cure Donald Trump of Covid-19 https://t.co/R9R7Pnq9bj
— Sabrina Courtez (@CourtezSabrina) October 19, 2020
Expert doctor on #Regeneron: #Trump also touted bleach for Covid-19https://t.co/mMjW64aa7O via @amjoyshow
— AM Joy on MSNBC (@amjoyshow) October 14, 2020
It takes just 1 sentence to know there's a big problem:
"A White House official told me that the president had “off the charts” antibodies on samples collected after he received the Regeneron infusion."https://t.co/lu05pnLZQp
No need @WhiteHouse or labhttps://t.co/HBCZBv5P8o— Eric Topol (@EricTopol) October 13, 2020
DON’T RT THIS VIDEO: THE MAGGOTS ARE MAD AT ME: Trump’s lie that Regeneron “cured” his Covid is also a scam: HE OWNED STOCK IN THE COMPANY; the CEO is a pal. And, what matters is Coney Barrett’s lies. Worst Person In The World #4 here: https://t.co/Th9jTg3L8l Short Version below: pic.twitter.com/kpDeJJlosE
— Keith Olbermann (@KeithOlbermann) October 13, 2020
https://twitter.com/jeff_cranmer/status/1317156952938434561
#Breaking: The FDA has approved our novel anti-viral #antibody medicine for Zaire ebolavirus in adult and pediatric patients. #Ebola Read the full announcement: https://t.co/a8S7QhXMBw pic.twitter.com/nHGrIvrzLH
— Regeneron (@Regeneron) October 14, 2020
Regeneron's #Inmazeb wins US #FDA approval as 1st #Ebola virus treatment @Regeneron https://t.co/AX9YDubXv2 pic.twitter.com/G7f1zrzSSq
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 15, 2020
An antibody cocktail from @Regeneron has been approved by the FDA as the first treatment for Ebola, offering hope that the same approach could be used to combat COVID-19. https://t.co/hDsBWDLueM
— pharmaphorum (@pharmaphorum) October 15, 2020
.@Regeneron's triple-antibody cocktail (REGN-EB3) on Wednesday became the first FDA-approved Zaire ebolavirus treatment: https://t.co/npE95ANizV pic.twitter.com/TlR3RWpugw
— Linksbridge (@linksbridge) October 15, 2020
Exciting news! @BARDA @US_FDA @Regeneron @doddtra https://t.co/HbXWZSMOFk
— CBD S&T Conference (@cbdstconference) October 16, 2020
The @US_FDA has granted approval to @Regeneron’s antibody drug Inmazeb for the treatment of Ebola virus, making it the first treatment for the virulent infection. Read more by @AyeshaR1202 here. https://t.co/l3bnBKhriC#FDA #Ebola #AntibodyDrug
— Xtalks Webinars (@Xtalks) October 19, 2020
This month the U.S. Food and Drug Administration granted formal approval to an antibody cocktail from the pharmaceutical company Regeneron that's been shown to dramatically reduce an Ebola patient's chances of dying. https://t.co/5c34CmtZZl
— NPR (@NPR) October 21, 2020
FDA has approved Regeneron 3 monoclonal antibodies cocktail for treating Ebola
The FDA has approved the first treatment for Ebolahttps://t.co/6TFsIVH1WF
— Randall French (@RandallFrench14) October 19, 2020
Yesterday, @US_FDA announced it has approved @Regeneron's Inmazeb, formerly called REGN-EB3, to treat Zaire ebolavirus infection in adult and pediatric patients — the first-ever FDA-approved treatment for #Ebola.https://t.co/mlJlGvPQTj
— ID News (@InfectDisNews) October 15, 2020
#Biotech #Ebola Regeneron's Inmazeb Becomes First Ebola Treatment To Get FDA Approval https://t.co/v11e1WoHqJ pic.twitter.com/mUPGKSEyAF
— dailytradingapp (@dailytradingapp) October 15, 2020
There's now an approved treatment for #Ebola Zaire, as well as a vaccine. Seemed unimaginable for a long time.
Regeneron's monoclonal cocktail, Inmazeb, was approved today by the FDA. https://t.co/TjAj0Ws6Te— Helen Branswell (@HelenBranswell) October 14, 2020
FDA approves first treatment for Ebola – it's Regeneron's antibody cocktail, the same approach Regeneron is now taking for #covid19: https://t.co/gn96D5G8WT
— Meg Tirrell (@megtirrell) October 14, 2020
The lines between reality and reality show have become so blurred that the (good!) news of the first #FDA-approved treatment for #Ebola feels like a bizarre cross-promotional product placement for #Regeneron (especially when #Remdesivir was one of the comparators). Still… (1/2) https://t.co/q9vloxSsRv
— Adam R Houston (@HealthLawAdamH) October 14, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
#DRG epidemiology report estimates more than 75 million people living with #atopicdermatitis across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #RevAtopDerm #SanofiActs @Regeneron @sanofi https://t.co/ClcF0WyNEE
— DRG Epidemiology (@DRG_Epi) April 9, 2020
#DRG epidemiology report estimates more than 20 million people diagnosed with #atopicdermatitis across the United States, Western Europe and Japan. Stay tuned for more epidemiology updates @DRGinsights #atopiceczema @Regeneron @sanofi https://t.co/b3WBojlYkZ
— DRG Epidemiology (@DRG_Epi) August 7, 2019
Japan’s MHLW extended #marketing and #manufacturing authorization for Regeneron’s #DUPIXENT https://t.co/giEc4TlxBi @regeneron pic.twitter.com/0sfqy4ZA8R
— Pharma Journalist (@pharmjournalist) January 24, 2018
.@regeneron has announced that Dupixent, a therapy for adult atopic dermatitis that is inadequately controlled by existing medications, has been granted marketing and manufacturing authorization by the Ministry of Health, Labor and Wealth in Japan.https://t.co/Ys1LSFol8c pic.twitter.com/9j9cu5Dz6R
— Rare Disease Report (@RareDR) January 23, 2018
#Sanofi and @Regeneron gain approval for PCSK9 inhibitor in Japan https://t.co/EnmPRhjXsD
— Sanofi (@sanofi) July 5, 2016
With thanks to Bronze Level Sponsors: Genentech Takeda @TaihoOncology @Regeneron pic.twitter.com/agr98dhoWN
— AA&MDSIF (@aamdsif) October 3, 2020
8-25-2020: Starting 4 months from now, Lilly's LY-CoV555, Regeneron's REGN-COV2, AstraZeneca's AZD7442, or Takeda/Behring/Octapharma might work for early COVID-19, be expensive, be vulnerable to mutations, and be in short supply:https://t.co/s29UYtb9o3https://t.co/ijHm26afc3
— Ronald M. Chavin (@rmchavin) August 25, 2020
Regeneron has started clinical trials with the dual cocktail, so let's see how that happens. Takeda is taking the approach of hyperimmune polyclonal serum. One issue with the polyclonal preps is maintaining consistency across batches.https://t.co/f7mPK6zNBT
— Thiago Carvalho (@CyrilPedia) July 3, 2020
Adimab broadens R&D deals with Novartis, Regeneron, Takedahttps://t.co/9gF1SqcuEq#R&D #novartis #regeneron #takeda #health #healthcare #pharmaceutical #digitalhealth #vitalyhealth
— Vitaly Health (@HealthVitaly) May 19, 2019
Takeda and Regeneron continue to tap into Adimab’s capabilities https://t.co/lIicDWO57S pic.twitter.com/bUbVGC5pmH
— JackLeckerman (@JackLeckerman) May 13, 2019
13 co's working on Coronavirus treatments/vaccines. Gilead's remdesivir is in late stage testing, GlaxoSmithKline is collaborating with Britain, U of Queensland. See also, Heat Biologics, Inovio, Johnson & Johnson, Moderna, Regeneron, Sanofi, Takeda, more. https://t.co/NyT4jixMES
— Dori Smith (@Dori_TalkNation) March 17, 2020
Biopharma's ever-evolving #COVID19 response, distilled:
Gilead, AbbVie, Pfizer looking at antivirals
J&J, Sanofi, and Moderna on vaccines
Regeneron, Eli Lilly, and Vir on antibodies
Takeda and Emergent on plasma therapyhttps://t.co/8S4Ucbc6ef— Andrew Dunn (@AndrewE_Dunn) March 13, 2020
and Pfizer Inc., and modest consultant/advisory board fees from Takeda, Medco, AstraZeneca, Resverlogix, Kowa, Abbvie, Eli Lilly, Sanofi, Amgen, Boehringer Ingelheim, Esperion, Cerenis, Akcea, and Regeneron Pharmaceuticals, Inc. https://t.co/NlIG9bHpHu
— Marion Holman (@holmanm) June 15, 2019
Adimab broadens R&D deals with Novartis, Regeneron, Takeda https://t.co/PLAwHC7tjz career medical device pic.twitter.com/cbGNbtODv1
— ThinKeen Global (@thinkeenglobal) May 8, 2019
SSPC GM @denise_croker and team have had a busy week discussing future opportunities for collaboration with Astellas Pharma Ireland, @SKbiotekIreland and @Regeneron @scienceirel #collaboration pic.twitter.com/ezqynt8H75
— SSPC (@SSPCentre) July 25, 2018
Thank you to everyone who support yesterday's Walk to End #Epilepsy, especially our fellow sponsors, including, @Regeneron, @Eisai_SDGs, @GreenwichBio, @EllisMedicine and Supernus. pic.twitter.com/vAAtOaSiw8
— Fingerpaint (@Fingerpainters) September 9, 2019
Great mix of pharma companies represented at @PharmacistsIER careers evening including AbbVie, Alexion, Aspen, Astellas, Bayer, BMS, GSK, Janssen, LEO Pharma, Mallinkcrodt, MSD, Perrigo, Pfizer, Novartis and Regeneron. https://t.co/M5SEwmHPAD
— PIER (@PharmacistsIER) November 1, 2018
Have you seen our @BioCentury Quick Takes? Here’s a look at April 20:
Top-line data for @bmsnews, Idorsia and Ascendis; plus Otsuka-Esperion, @Regeneron and more… https://t.co/ctlZkt7zyV
— matt krebs (@krebs_matt) April 21, 2020
Monday's Quick Takes: top-line data for BMS, Idorsia and Ascendis; plus Otsuka gains Japan rights to Esperioin drugs for $60M upfront and news from Regeneron, Biofourmis and Galapagos $ASND $REGN $BMY $ESPR https://t.co/lu9xn0VCTM
— BioCentury (@BioCentury) April 21, 2020
